Rheumatoide Arthritis: Beobachtung der Biologika-Therapie
  General Information
 What is it about?

 Survey

 Biologics in RA-Therapy

 What is long-term observation?

 Conception of RABBIT

 Data-obtaining instruments

 Information on sponsorship

 Data protection

 Reporting on RABBIT


 Homepage

 General Information

 Documentation Forms

 Publications

 Risk Score

 Additional European Registers

 Contact

  Imprint



sprache ändern:

deutsch
 
  

What is it about?


  

Objectives of RABBIT:

  1. Description of long-term efficacy of a treatment with biologics, of time spent under therapy, of reasons for a change in therapy as well as description of disease course under therapy and where applicable after end of therapy
  2. Examination of long-term outcomes of biologic therapy compared to conventional DMARD therapy
  3. Determination of direct and indirect costs of biologic therapy compared to conventional DMARD therapy

Design of RABBIT:
  • prospective observational study with internal control group
  • biologic group
  • control group (those who change from one DMARD to another)
  • observation period: at least 5 years
  • measuring instruments: DAS28; ACR Response Criteria; continuity of therapy; record of adverse events; work disability and many more

Biologics: All biologics approved for the treatment of RA in Germany.

Time required:

  • In the first year: for all measurements (altogether) 1 hour per patient maximum
  • From the second year on: 30-45 minutes per patient



        

Basic research - immunocompetent cells

Milzgewebe/Maus; T-Zellen (grün) und B-Zellen (blau)

spleen/mouse T-cells (green) B-cells (blue)

Milzgewebe/Maus; Granulozyten (magenta) und Zellkerne (blau)

section from above x1000 magnification